RECURRENT PLASMA CELL MYELOMA
Clinical trials for RECURRENT PLASMA CELL MYELOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT PLASMA CELL MYELOMA trials appear
Sign up with your email to follow new studies for RECURRENT PLASMA CELL MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail shows promise in battling returned bone marrow cancer
Disease control CompletedThis study tested a drug called ixazomib, alone or with other medicines, in 165 people whose multiple myeloma (a type of blood cancer) had come back. The goal was to see if these combinations could shrink or control the cancer. Participants received different treatment plans, and…
Matched conditions: RECURRENT PLASMA CELL MYELOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 16, 2026 20:03 UTC
-
New combo offers hope for Hard-to-Treat blood cancers
Disease control CompletedThis early-stage trial tested a combination of two drugs—selinexor and choline salicylate—in 22 adults with certain blood cancers (like lymphoma and multiple myeloma) that came back or didn't respond to prior therapy. The main goal was to find the safest dose and see how well pat…
Matched conditions: RECURRENT PLASMA CELL MYELOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 16, 2026 20:03 UTC
-
Stem cell transplant study seeks best way to prevent immune attack
Disease control CompletedThis study tested different drug combinations to prevent graft-versus-host disease (GVHD) in 174 people with blood cancers receiving stem cells from an unrelated donor. GVHD is a serious side effect where donor cells attack the patient's body. The goal was to find which drug regi…
Matched conditions: RECURRENT PLASMA CELL MYELOMA
Phase: PHASE3 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC
-
Can nivolumab fight blood cancers that come back after CAR t?
Disease control CompletedThis study tested the drug nivolumab in 20 adults with blood cancers (like lymphoma, leukemia, or myeloma) that returned or did not respond after CAR T-cell therapy. Nivolumab is an immunotherapy that helps the body's immune system attack cancer cells. The goal was to see if it c…
Matched conditions: RECURRENT PLASMA CELL MYELOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 11, 2026 12:11 UTC